Cargando…
Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
BACKGROUND: Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor and is used in combination with first-line chemotherapy in the treatment of metastatic colorectal cancer. One of the side effects of bevacizumab is gastrointestinal perforation. This study was desig...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639472/ https://www.ncbi.nlm.nih.gov/pubmed/36353568 http://dx.doi.org/10.3389/fonc.2022.1018458 |
_version_ | 1784825648917774336 |
---|---|
author | Kim, Seijong Shin, Jung Kyong Park, Yoonah Huh, Jung Wook Kim, Hee Cheol Yun, Seong Hyeon Lee, Woo Yong Cho, Yong Beom |
author_facet | Kim, Seijong Shin, Jung Kyong Park, Yoonah Huh, Jung Wook Kim, Hee Cheol Yun, Seong Hyeon Lee, Woo Yong Cho, Yong Beom |
author_sort | Kim, Seijong |
collection | PubMed |
description | BACKGROUND: Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor and is used in combination with first-line chemotherapy in the treatment of metastatic colorectal cancer. One of the side effects of bevacizumab is gastrointestinal perforation. This study was designed to identify the effect of bevacizumab in intestinal anastomosis site healing. METHODS: From January 2010 to December 2020, patients diagnosed with stage IV colorectal cancer treated with palliative chemotherapy or chemoradiotherapy followed by radical surgery were retrospectively reviewed. Clinical signs or symptoms and computed tomography were tools used for diagnosing anastomosis site leakage. The patients were divided into two groups, the bevacizumab group (n = 136) and the non-bevacizumab group (n = 124). RESULTS: Among the 260 patients 14 (5.4%) patients were diagnosed with anastomosis site leakage. In the bevacizumab group, 13 (9.6%) patients were diagnosed with anastomotic leakage. In the non-bevacizumab group, 1 (0.8%) patient was diagnosed with anastomotic leakage. Anastomosis site leakage was significantly higher in the bevacizumab treatment group (P < 0.001). In the bevacizumab group, period of drug discontinuation before surgery was factor associated with anastomosis site leakage in multivariable analysis (P = 0.031). CONCLUSION: Stage IV colorectal patients treated with bevacizumab before radical surgery for primary cancer should be carefully observed of anastomosis site leakage after surgery, and the period of drug discontinuation before surgery should be longer than 5 weeks to avoid anastomosis site leakage. |
format | Online Article Text |
id | pubmed-9639472 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96394722022-11-08 Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer Kim, Seijong Shin, Jung Kyong Park, Yoonah Huh, Jung Wook Kim, Hee Cheol Yun, Seong Hyeon Lee, Woo Yong Cho, Yong Beom Front Oncol Oncology BACKGROUND: Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor and is used in combination with first-line chemotherapy in the treatment of metastatic colorectal cancer. One of the side effects of bevacizumab is gastrointestinal perforation. This study was designed to identify the effect of bevacizumab in intestinal anastomosis site healing. METHODS: From January 2010 to December 2020, patients diagnosed with stage IV colorectal cancer treated with palliative chemotherapy or chemoradiotherapy followed by radical surgery were retrospectively reviewed. Clinical signs or symptoms and computed tomography were tools used for diagnosing anastomosis site leakage. The patients were divided into two groups, the bevacizumab group (n = 136) and the non-bevacizumab group (n = 124). RESULTS: Among the 260 patients 14 (5.4%) patients were diagnosed with anastomosis site leakage. In the bevacizumab group, 13 (9.6%) patients were diagnosed with anastomotic leakage. In the non-bevacizumab group, 1 (0.8%) patient was diagnosed with anastomotic leakage. Anastomosis site leakage was significantly higher in the bevacizumab treatment group (P < 0.001). In the bevacizumab group, period of drug discontinuation before surgery was factor associated with anastomosis site leakage in multivariable analysis (P = 0.031). CONCLUSION: Stage IV colorectal patients treated with bevacizumab before radical surgery for primary cancer should be carefully observed of anastomosis site leakage after surgery, and the period of drug discontinuation before surgery should be longer than 5 weeks to avoid anastomosis site leakage. Frontiers Media S.A. 2022-10-21 /pmc/articles/PMC9639472/ /pubmed/36353568 http://dx.doi.org/10.3389/fonc.2022.1018458 Text en Copyright © 2022 Kim, Shin, Park, Huh, Kim, Yun, Lee and Cho https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Kim, Seijong Shin, Jung Kyong Park, Yoonah Huh, Jung Wook Kim, Hee Cheol Yun, Seong Hyeon Lee, Woo Yong Cho, Yong Beom Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer |
title | Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer |
title_full | Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer |
title_fullStr | Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer |
title_full_unstemmed | Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer |
title_short | Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer |
title_sort | bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639472/ https://www.ncbi.nlm.nih.gov/pubmed/36353568 http://dx.doi.org/10.3389/fonc.2022.1018458 |
work_keys_str_mv | AT kimseijong bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer AT shinjungkyong bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer AT parkyoonah bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer AT huhjungwook bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer AT kimheecheol bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer AT yunseonghyeon bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer AT leewooyong bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer AT choyongbeom bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer |